Date Range
toReport Types
Condition
Region of the Body
See all (5)
Specialties
See all (18)
Emerging Treatments
OE Recommends Topics
Multimedia
Journal
Conference Series
Evidence Series
Antiresorptive effects of single zoledronate dose are sustained for 3 years
J Bone Miner Res. 2010 Oct;25(10):2251-5
Substantial anti-resorptive effects achieved with 1mg and 2.5mg doses of zoledronate
J Clin Endocrinol Metab. 2012 Jan;97(1):286-92. doi: 10.1210/jc.2011-2081. Epub 2011 Nov 9
Effects of 2.5mg zoledronate are long-lasting and similar to 5mg dose in osteopenic women
J Bone Miner Res. 2014 Jan;29(1):166-72. doi: 10.1002/jbmr.2009.
Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia
N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082
Zoledronate reduces radiation-induced bone collagen degradation in radiation therapy
Clin Transl Oncol. 2015 Jun;17(6):454-61.
Alendronate & zoledronate both reduce hip and vertebral fracture risk compared to placebo
Gynecol Endocrinol. 2013 Dec;29(12):1005-14. doi: 10.3109/09513590.2013.813468. Epub 2013 Sep 25
Zoledronic acid increases BMD at tibial epiphysis, but not tibial diaphysis
Maturitas. 2014 Mar;77(3):287-93
Network meta-analysis of current drug options for the treatment of osteoporosis in men
PLoS One. 2015 May 26;10(5):e0128032
Bisphosphonates do not reduce joint failure or THA in femoral head osteonecrosis patients
Osteoporos Int. 2016 Jan;27(1):295-9
Comparison of risedronate, alendronate, zoledronate, and ibandronate in those with low BMD
Bone. 2016 Aug;89:52-8
Bisphosphonates prevent periprosthetic bone loss following arthroplasty over the mid-term
Osteoporos Int. 2012 Jun;23(6):1823-34. doi: 10.1007/s00198-011-1797-5. Epub 2011 Sep 20
Bisphosphonates effective in osteoporotic males in terms of fracture, BMD, and biomarkers
Osteoporos Int. 2015 Sep;26(9):2355-63.
Bone mineral density loss following total joint arthroplasty mitigated by bisphosphonate therapy
Osteoporos Int. 2018 Jul;29(7):1525-1537. doi: 10.1007/s00198-018-4488-7
Bisphosphates to prevent femoral periprosthetic bone resorption after cementless THA
J Orthop Surg Res. 2015 May 13;10(1):65
Network meta-analysis of anti-osteoporosis therapies for oral glucocorticoid users
Osteoporos Int. 2016 Jun;27(6):1989-98
Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates
J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70